Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

The news comes as Pfizer is trying to catch up with U.K.-based GlaxoSmithKline (GSK). Its RSV vaccine for adults was approved by the FDA in May. The company is already undergoing priority review with ...

DNA submitted by users to the genealogy company 23andMe will remain private for now, with CEO Anne Wojcicki saying she no ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire board of directors resigned over disagreements with the CEO. That CEO, Anne ...

The once-hot Silicon Valley startup has seen its stock’s value decline 99% and is struggling to survive. That has put the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In this month's trial, which began on Aug. 28, Eric Olson ( Olson Grimsley) and Ashley Keller ( Keller Postman) represented ...

With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK turned the mobile phone into a disease detection and risk evaluation tool to raise awareness of under-diagnosed and under-treated chronic obstructive pulmonary disease in China. GSK has always ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

"My life was hell": Man awarded £160,000 damages after Parkinson's drug turned him into gay sex and gambling addict ...